Account
Insider Insights
14.03.2023
Newly agreed Windsor Framework carries significant...

Windsor Framework replaces the Northern Ireland protocol to address issues and provide significant c...

Read more
Insider Insights
09.03.2023
What has occurred in the past year in the Swedish ...

TLV unveils annual report, offering insights into trends and projects that have dominated the past y...

Read more
Insider Insights
09.03.2023
NICE issues conditional recommendation for digital...

NICE conditionally recommends eight digitally enabled therapies to treat depression and anxiety in a...

Read more
Articles
07.03.2023
Are acute therapies and curative drugs more afford...

We've prepared an analysis of the top 10 most expensive drugs in the US compared with Germany, in th...

Read more
Insider Insights
02.03.2023
ABPI sets out new proposals in VPAG

ABPI announces new VPAG, which focuses on restoring the commercially competitive environment for lif...

Read more
Insider Insights
24.02.2023
The EU has a new project to find payment models fo...

Project to help the EU develop new pricing and payment models to fund high-priced drugs and relieve ...

Read more
Insider Insights
22.02.2023
NICE announces the development of a new rapid revi...

New process to assess clinical and cost-effectiveness of COVID-19 treatments to get these medicines ...

Read more
Articles
22.02.2023
What are the risks and benefits of Early Access Pr...

Using Early Access Programs (EAPs) to give patients with life threatening conditions access to medic...

Read more
Articles
15.02.2023
What early access opportunities exist for innovati...

Our Market Access experts investigate what early access opportunities are available in China to enab...

Read more
Insider Insights
08.02.2023
First Adalimumab Biosimilar Launch in the USA

The first adalimumab (branded Humira) biosimilar, Amjevita, has been launched in the US by pharmaceu...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.